Introduction: Investigating New Pathways for Eating Disorders

Recent research explores the potential of CBD for Anorexia Nervosa as a novel therapeutic intervention. Anorexia nervosa (AN) remains a challenging psychiatric condition. It features intense fear of weight gain and severe body dissatisfaction. Because current pharmacological treatments often fail to address these core symptoms, clinicians are looking toward the endocannabinoid system. Specifically, cannabidiol (CBD) offers hope due to its potential to modulate anxiety and appetite without the intoxicating effects of THC.

Study Design and Methodology

Researchers conducted a double-blind, randomized placebo-controlled pilot study involving 32 women. These participants met the criteria for AN or atypical AN. The team assigned 16 women to the CBD group and 16 to a placebo group for a 21-day period. Furthermore, the protocol involved a weekly up-titration of the dose. It began at 1.25 mg/kg twice daily and reached a maximum of 6.25 mg/kg twice daily. During this time, investigators monitored liver function, metabolite levels, and psychiatric symptoms closely.

Impact of CBD for Anorexia Nervosa on BMI and Symptoms

Notably, the results showed that CBD is safe and well-tolerated. The pharmacokinetic data aligned with expectations, showing limited and nonserious adverse events. Most importantly, a repeated measures MANCOVA revealed a significant group-by-time interaction for BMI increase (p = 0.046). Consequently, those receiving CBD demonstrated better weight recovery compared to the placebo group. In addition, the researchers observed large effect sizes for improvements in shape concern and perception of eating control. Although these specific symptom changes did not reach statistical significance in this small sample, the trends favor CBD as a supportive treatment.

Discussion and Future Outlook

This pilot study suggests that CBD might stabilize weight and improve eating disorder cognitions. However, the researchers acknowledge significant constraints. Specifically, the small sample size and short duration limit the generalizability of these findings. Therefore, larger clinical trials are necessary to confirm these preliminary benefits. If replicated, CBD for Anorexia Nervosa could become a vital tool for clinicians managing this high-mortality disorder.

Frequently Asked Questions

Is CBD safe for patients with Anorexia Nervosa?

According to this pilot study, CBD was well-tolerated with only nonserious adverse events reported. However, liver function must be monitored during treatment, especially when using higher doses.

Does CBD significantly increase weight in Anorexia patients?

The study found a small but statistically significant increase in BMI in the CBD group compared to the placebo group over 21 days, indicating potential for aiding weight restoration.

Can CBD help with the psychological symptoms of eating disorders?

While the study showed large effect sizes for improvements in shape concern and control over eating, these results were not statistically significant due to the small sample size. More research is needed to confirm these cognitive benefits.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sahota N et al. Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. Int J Eat Disord. 2026 Mar 29. doi: 10.1002/eat.70034. PMID: 41906184.

ClinicalTrials.gov. The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervosa: Safety, Tolerability and Pharmacokinetics. Identifier: NCT04878627.

Frank GK et al. Innovative and Emerging Treatments for Anorexia Nervosa. PMC NIH. 2023. doi: 10.1016/j.psc.2022.10.003.